SecBot SecBot
8-K ·Filed May 6, 2026

NVAX

NOVAVAX INC
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001628280-26-030924
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Revenue and EPS beat consensus estimates, but the comparison is distorted by the prior-year APA close-out. The reiteration of FY2026 guidance provides no new catalyst. Watch for Sanofi milestone payments (up to $350M for flu-COVID combo, $75M tech transfer milestone) and further Matrix-M partnership announcements as the primary upside drivers. The $795M cash position and $330M credit facility provide runway through the transition.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.36
T+0 close · May 6, 2026 · via day close
Latest settled
−21.79%
T+60 · $7.32
Vs SPY
−23.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $9.36entry
  2. T+1 · 6mo ago −1.39%α −1.06% · $9.23
  3. T+5 · 6mo ago +2.78%α +1.65% · $9.62
  4. T+20 · 6mo ago +8.97%α +6.19% · $10.20
  5. T+60 · 4mo ago −21.79%α −23.86% · $7.32
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Novavax reported Q1 2026 total revenue of $140M, down 79% YoY from $667M, which included $603M in non-cash APA close-out sales in Q1 2025. Net loss was $9M vs net income of $519M in the prior year. The company reiterated its FY2026 adjusted total revenue framework of $230M-$270M and expense guidance, with no change to outlook. The headline revenue decline is entirely driven by the prior-year APA close-out, not underlying business deterioration.

Key Financial Metrics

EPS
−$0.06
est −$0.25 · +76.0%
Revenue
$139.5M
est $81.0M · +72.2% · -79.0% YoY
Rating
in line
Guidance
$230M-$270M (adjusted total revenue)
maintained

Key Facts

  • Q1 2026 total revenue $140M, down 79% YoY from $667M (Q1 2025 included $603M non-cash APA close-out)
  • Q1 2026 net loss $9M vs net income $519M in Q1 2025
  • GAAP diluted EPS $(0.06) vs $2.93 in Q1 2025
  • Licensing, royalties and other revenue $97M, up 116% YoY, including $30M Pfizer upfront
  • Cash and marketable securities $795M at March 31, 2026, up from $751M at Dec 31, 2025
  • Reiterated FY2026 adjusted total revenue guidance of $230M-$270M
  • Reiterated FY2026 Non-GAAP combined R&D and SG&A expense guidance of $310M-$340M
  • Signed new MTAs in April 2026 with a top 10 pharma company for oncology and infectious disease targets
  • Sanofi announced positive Phase 4 COMPARE study results for Nuvaxovid vs Moderna's mNEXSPIKE

Financial Impact

Q1 2026 revenue $140M vs consensus $81M (beat), but GAAP EPS $(0.06) vs consensus $(0.25) (beat). The 79% YoY revenue decline is non-comparable due to $603M APA close-out in Q1 2025.

revenueepsnet income

Risk Factors

  • Dependence on Sanofi for commercial execution and revenue forecasts, no guidance on Sanofi-related revenue components
  • COVID-19 vaccine demand remains seasonal and unpredictable
  • Nuvaxovid product sales declining 98% YoY as commercial lead transitions to Sanofi
  • Stockholders' deficit of $145M at March 31, 2026, though improving from $128M at year-end 2025
  • Convertible notes payable increased to $291M from $244M at year-end 2025

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
67% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-030924
Document: nvax-20260506.htm0001628280-26-030924
Document: 0001628280-26-030924-index-headers.html0001628280-26-030924
Document: 0001628280-26-030924-index.html0001628280-26-030924
Document: 0001628280-26-030924.txt0001628280-26-030924
8-K Data (Synthetic)0001628280-26-030924

Track record

9 reports on NVAX

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +25.51% at T+20 after the Oct 16, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $10.20 Now $8.06 −20.98% settles Nov 17
  2. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $9.78 to $8.76 Now $8.06 −17.59% ▼ −10.43% −13.72% vs SPY
  3. Oct 29, 202618d ago 8-K Bullish 5/10 Entry $10.08 to $10.78 Now $8.06 −20.04% ▲ +6.94% +9.65% vs SPY
  4. Oct 16, 20264w ago SC 13G Neutral 4/10 Entry $10.82 to $9.40 Now $8.06 −25.51% ▼ −13.12% −12.98% vs SPY
  5. Oct 16, 20264w ago SC 13D/A Bearish 6/10 Entry $10.82 to $9.40 Now $8.06 +25.51% ▲ +13.12% +12.98% vs SPY
  6. Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.74 to $8.14 Now $8.06 +4.13% ▲ +5.17% +3.96% vs SPY
  7. May 6, 202627w ago 8-K Neutral 4/10 Viewing Entry $9.36 to $9.62 Now $8.06 −13.89% ▲ +2.78% +1.65% vs SPY
  8. Apr 27, 202629w ago DEFA14A Neutral 2/10 Entry $8.07 to $8.03 Now $8.06 −0.12% ▼ −0.50% −0.90% vs SPY
  9. Feb 26, 202637w ago 8-K Bullish 8/10 Entry $11.19 to $9.99 Now $8.06 −27.97% ▼ −10.72% −9.60% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026